215 related articles for article (PubMed ID: 17483317)
1. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.
Boylan KL; Gosse MA; Staggs SE; Janz S; Grindle S; Kansas GS; Van Ness BG
Cancer Res; 2007 May; 67(9):4069-78. PubMed ID: 17483317
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia.
Park ES; Shaughnessy JD; Gupta S; Wang H; Lee JS; Woo HG; Zhan F; Owens JD; Potter M; Janz S; Mushinski JF
BMC Genomics; 2007 Aug; 8():302. PubMed ID: 17764563
[TBL] [Abstract][Full Text] [Related]
3. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice.
Linden M; Kirchhof N; Kvitrud M; Van Ness B
Leuk Res; 2005 Apr; 29(4):435-44. PubMed ID: 15725478
[TBL] [Abstract][Full Text] [Related]
4. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.
Cheung WC; Kim JS; Linden M; Peng L; Van Ness B; Polakiewicz RD; Janz S
J Clin Invest; 2004 Jun; 113(12):1763-73. PubMed ID: 15199411
[TBL] [Abstract][Full Text] [Related]
5. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells.
Gauthier ER; Piché L; Lemieux G; Lemieux R
Cancer Res; 1996 Mar; 56(6):1451-6. PubMed ID: 8640839
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells.
Qi CF; Zhou JX; Lee CH; Naghashfar Z; Xiang S; Kovalchuk AL; Fredrickson TN; Hartley JW; Roopenian DC; Davidson WF; Janz S; Morse HC
Cancer Res; 2007 Mar; 67(6):2439-47. PubMed ID: 17363561
[TBL] [Abstract][Full Text] [Related]
7. Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies.
Linden M; Kirchhof N; Carlson C; Van Ness B
Blood; 2004 Apr; 103(7):2779-86. PubMed ID: 14656874
[TBL] [Abstract][Full Text] [Related]
8. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
Stessman HA; Baughn LB; Sarver A; Xia T; Deshpande R; Mansoor A; Walsh SA; Sunderland JJ; Dolloff NG; Linden MA; Zhan F; Janz S; Myers CL; Van Ness BG
Mol Cancer Ther; 2013 Jun; 12(6):1140-50. PubMed ID: 23536725
[TBL] [Abstract][Full Text] [Related]
9. Distinguishing primary and secondary translocations in multiple myeloma.
Gabrea A; Leif Bergsagel P; Michael Kuehl W
DNA Repair (Amst); 2006 Sep; 5(9-10):1225-33. PubMed ID: 16829212
[TBL] [Abstract][Full Text] [Related]
10. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
11. Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation.
McNeil N; Kim JS; Ried T; Janz S
Genes Chromosomes Cancer; 2005 Jun; 43(2):137-46. PubMed ID: 15751044
[TBL] [Abstract][Full Text] [Related]
12. NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors.
McCarthy BA; Yang L; Ding J; Ren M; King W; ElSalanty M; Zakhary I; Sharawy M; Cui H; Ding HF
BMC Cancer; 2012 May; 12():203. PubMed ID: 22642622
[TBL] [Abstract][Full Text] [Related]
13. BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations.
Silva S; Kovalchuk AL; Kim JS; Klein G; Janz S
Cancer Res; 2003 Dec; 63(24):8656-63. PubMed ID: 14695177
[TBL] [Abstract][Full Text] [Related]
14. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.
Glassford J; Rabin N; Lam EW; Yong KL
Br J Haematol; 2007 Oct; 139(2):243-54. PubMed ID: 17897300
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of a cytogenetically complex Chinese multiple myeloma-derived cell line with homozygous p53 deletion and cyclin E overexpression.
Cheng SH; Ng MH; Tsang KS; Lau KM; Chan JC; Liu HS; Chu RW; Poon CS; Ng HK
Int J Oncol; 2004 May; 24(5):1141-8. PubMed ID: 15067335
[TBL] [Abstract][Full Text] [Related]
16. Myc translocations in B cell and plasma cell neoplasms.
Janz S
DNA Repair (Amst); 2006 Sep; 5(9-10):1213-24. PubMed ID: 16815105
[TBL] [Abstract][Full Text] [Related]
17. Molecular biology of myeloma.
Gutiérrez NC; García-Sanz R; San Miguel JF
Clin Transl Oncol; 2007 Oct; 9(10):618-24. PubMed ID: 17974522
[TBL] [Abstract][Full Text] [Related]
18. CD31 expression in plasmacytic/plasmablastic lesions.
Plocharczyk E; Wakely PE
Ann Diagn Pathol; 2013 Dec; 17(6):498-501. PubMed ID: 24074836
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on the origins of multiple myeloma and plasmacytomas in mice.
Potter M
Hematol Oncol Clin North Am; 1992 Apr; 6(2):211-23. PubMed ID: 1582969
[TBL] [Abstract][Full Text] [Related]
20. Plasma cell tumour progression in iMycEmu gene-insertion mice.
Kim JS; Han SS; Park SS; McNeil N; Janz S
J Pathol; 2006 May; 209(1):44-55. PubMed ID: 16482495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
